Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: A four-centre non-interventional study

Journal of Medical Economics

Volumn 13, Issue 1, 2010, Pages 162-167

  Houston, S ^a   Grieve, R J ^b   Hickish, T ^c   Percival, F ^d   Hamilton, E ^e  

^a St Luke's Cancer Centre   (United Kingdom)

^b UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^c BOURNEMOUTH UNIVERSITY   (United Kingdom)

^d PH ASSOCIATES   (United Kingdom)

^e ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Biphosphonates; Breast neoplasms; Health resources; Ibandronic acid; Renal insufficiency; Zoledronic acid

Indexed keywords

IBANDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG COST; DRUG DOSE REDUCTION; HOSPITALIZATION COST; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NATIONAL HEALTH SERVICE;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY FUNCTION TESTS; MIDDLE AGED; RENAL INSUFFICIENCY; STATE MEDICINE;

EID: 77149169463     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696991003640383     Document Type: Article

References (22)

1. Cazzaniga ME, Dogliotti L, Cascinu S, et al. Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter Study. Oncology 2006;71:374-381
2. Body J, Diel IJ, Lichinitser MR, et al. Intravenous ibandronic acid reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 2003;14:1399-1405
3. Cameron Fallon M, Diel I. Ibandronic acid: its role in metastatic breast cancer. Oncologist 2006;11(Suppl 1):27-33
4. Cameron D. Patient management issues in metastatic bone disease. Semin Oncol 2004;31:79-82
5. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendation of an international expert panel. Ann Oncol 2008;19:420-432
6. Pecherstorfer M. Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update. Expert OpinPharmacother 2008;9:3111-3119
7. Corso A, Zappasodi P, Lazzarino M. Urinary proteins and renal dysfunction in patients with multiple myeloma. Biomed Pharmacother 2002;56:139-143
8. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Safety 2001;24:19-38
9. McCormack PL, Plosker GL. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. Drugs 2006;66:711-728
10. Munier A, Gras V, Andrejak M, et al. Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 2005;39:1194-1197
11. Johnson KB, Gable P, Kaime EM, et al. Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. Proc Am Soc Clin Oncol 2003;22:738 (Abstr 2968)
12. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679
13. Novartis Pharmaceuticals. Summary of Product Characteristics, Zometa 4 mg/5 ml concentrate for solution for infusion, 19 January 2009
14. Pecherstorfer M, Rivkin S, Body JJ, et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer an open-label trial. Clin Drug Invest 2006;26:315-322
15. McLachlan SA, Cameron D, Murray R, et al. Safety of oral ibandronate in the treatment of bone metastases from breast cancer. Clin Drug Invest 2006;26:43-48
16. Roche Products Ltd. Summary of Product Characteristics, Bondronat 50 mg tablets, 25 September 2007
17. Ibid
18. NHS Reference costs 2006-2007. Available at: http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/Publications-PolicyAndGuidance/DH-082571 (accessed 18.1.10)
19. Serum creatinine. Available at: http://www.RNCEUS.com/renal/renalcreat. html (accessed 18.1.10)
20. Schmidt M, Seraphin J, Luhn B, Soeling U. Renal safety and sustained bone pain effectiveness of ibandronate in breast cancer patients with metastatic bone disease: interim results of a non-interventional study in Germany. ePoster presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, USA, December 10-14, 2008
21. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
22. Body J, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist 2005;10(Suppl 1):3-7